Stanford Health Care
About Stanford Clinical LaboratoryLicensureContact Us

Home
Test Directory

Test Requisitions Specimen Collection
Critical Values
Administrative Department
Clinical DepartmentsDepartment of PathologyEsoteric DepartmentsFeatured Services



BLADDER CANCER FISH, UROVYSION

Test Code: CGFi UROV
General Information: Transitional cell carcinoma (TCC) constitutes 90% of human bladder cancer, 75% of which are considered “superficial”, i.e., carcinoma in situ, non-invasive papillary TCC or minimally invasive TCC. Recurrence of superficial TCC or progression to muscle invasive TCC occurs in 50-80% and 15-25% of cases, respectively. Patients with TCC are monitored with cystoscopy and/or urine cytology for recurrent disease, both of which are relatively insensitive methods of testing. Numerous studies have correlated various chromosomal aneuploidies with TCC. Fluorescence in situ hybridization (FISH) using a variety of probes has been utilized for detection of aneuploidies on cells from voided urine. The UroVysion Bladder Cancer Screening Kit (Abbott, Vysis) provides a FISH probe mixture that includes centromeric probes for chromosomes #3, #7 and #17 and a unique sequence probe for the p16 gene (located at 9p21). Specifically, concurrent extra copies of two or more chromosomes and/or loss of 9p21 are consistent with a diagnosis of recurrent TCC.

 
 


 
Home | About Stanford Clinical Laboratories | Careers | Contact Us | Legal Notices & Disclaimer